A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease

Conditions

• Moderate to Severe Chronic Obstructive Pulmonary Disease

Eligibility Criteria

Sex

ALL

Age

35 Years - 80 Years

Healthy Volunteers

Not accepted

Interventions

• PF-07275315 dose 1 — DRUG
  SC injection dose 1
• PF-07275315-dose 2 — DRUG
  SC injection dose 2
• Placebo — DRUG
  SC injection matched
• PF-07275315-dose 3 — DRUG
  SC injection dose 3

Study Details

The purpose of this clinical trial is to learn about the effects and safety of the study medicine PF-07275315 for the potential treatment of COPD. COPD is a condition that makes it difficult to breathe, which negatively impacts the quality of life and functioning of people who are affected. This study is seeking participants who: * Are 35 to 80 years old * Have had moderate-to-severe COPD for at least 12 months * Have a documented history of at least 2 moderate or severe exacerbations within the last 12 months * Have been continuously taking their regular maintenance treatment(s) for COPD over at least 6 months at a stable dose for 3 months All participants will receive PF-07275315 or a placebo. A placebo does not have any medicine in it but looks just like the medicine being studied. PF-07275315 or placebo will be given as multiple shots in the clinic over the course of 24 weeks for the Phase 2 part and 52 weeks for the Phase 3 part. We will compare the results of people receiving PF-07275315 to those of the people who do not. This will help us determine if PF-07275315 is safe and effective. Participants who will be involved in the Phase 2 part of the study for about 40 weeks. During this time, they will have 11 visits at the study clinic. Participants who will be involved in the Phase 3 part of the study for about 68 weeks. During this time, they will have 18 visits at the study clinic.

Key Dates

Start date

Feb 11, 2026

Status verified

Mar 2026

Primary completion

Oct 24, 2030

Completion

Jan 16, 2031

Study Design

Enrollment

1,156 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Phase 2 Treatment Arm A
• Experimental: Phase 2 Treatment Arm B
• Placebo Comparator: Phase 2 Treatment Arm C
• Experimental: Phase 3 Treatment Arm A
• Placebo Comparator: Phase 3 Treatment Arm B

Primary Outcome Measure

Phase 2 part: Change from baseline in pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 24 [ Time Frame: Baseline to Week 24 ]

Central Contacts

• Pfizer CT.gov Call Center
  1-800-718-1021
  [email protected]

Locations (30)

Find similar trials in Dothan, AL